Live
Funding 2 min read

Fresh out of stealth, Switchpoint Bio raises €4.75 million to decode disease and drug response through blood tests

Switchpoint Bio, a Helsinki- and Cambridge-based TechBio startup, has secured €4.75 million in pre-Seed funding to develop its blood-based epigenomic platform aimed at revolutionizing drug response analysis. The round included significant backing from Treehouse Delmar Investments.

Image: EU-Startups Finland

Switchpoint Bio has raised €4.75 million in pre-Seed financing aimed at enhancing its blood-based epigenomic platform. This funding, which includes a substantial €4.48 million investment from Treehouse Delmar Investments, is expected to aid the company in transforming how drug developers understand disease responses and treatment effects in patients.

The Helsinki- and Cambridge-based startup was founded by PhD researchers from Stanford University, including MacArthur Fellow Jason Buenrostro and Samuel Myllykangas, who previously scaled Blueprint Genetics. Their innovative approach uses circulating immune cells that reflect epigenomic changes, providing drug developers vital insights into therapeutic strategies.

Following this significant funding, Switchpoint Bio is positioned to advance its technology, which could transform drug response analysis in the pharmaceutical industry.

Reporting sources

Where this story comes from

1 reference

The facts above are grounded in the original reporting linked here. Open the publisher story for its complete context.

EU-Startups Finland Open source

Fresh out of stealth, Switchpoint Bio raises €4.75 million to decode disease and drug response through blood tests

The available publisher preview does not add detail beyond this brief. Open the original report for its full context.

Related coverage

Story history

No reviewed connections found in the current history window.

About this history review

The link graph’s cryptographic signature was verified. This proves integrity, not the truth of every claim or complete archive coverage.

Graph updated . Only articles retained in the public archive are included.

Open technical link data
Method & transparencyHow this brief was selected and checked
Editorial priority7 / 10

Priority

Source coverageSingle-source report

Single-source report

ConfidenceLimited

43 / 100 · one source

Source basis

Grounded in the publisher material listed below.

Confirmation

No second independent source has been matched to this story yet.

Selection

Selected for publication after relevance, freshness and editorial-quality checks.

Selection factors

  • 1 independent source
  • 3 concrete event indicators
  • editorial priority

Source monitoring: 96% recent availability · No source-health warnings. The original publisher remains the authoritative source for the full report.